Oralair (Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate)

The extract is placed under the tongue, where it contacts oral mucosal immune cells. Repeated low‑dose exposure promotes regulatory T‑cell development and increases allergen‑specific IgG4 antibodies, shifting the immune response away from an IgE‑driven allergic pathway and fostering long‑term tolerance to grass pollen.

The dosing regimen for Oralair is individualized by the prescribing clinician based on the patient’s age, severity of symptoms, and treatment protocol. The prescriber determines the starting dose, titration schedule, and maintenance dose, which are not standardized across all patients.

Safety data for Oralair in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so clinicians must weigh potential benefits against possible risks. Breastfeeding mothers should consider the lack of definitive safety information and discuss options with their healthcare provider.

To request Oralair, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify institutional credentials, provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Oralair is a sublingual tablet, offering the convenience of at‑home administration compared with subcutaneous immunotherapy (SCIT), which requires clinic visits for injections. Compared with other SLIT tablets such as Grastek, Oralair contains a broader mix of grass species and follows a distinct dosing schedule, but both aim to achieve long‑term tolerance.

Oralair tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture, heat and direct sunlight. Do not refrigerate or freeze the tablets, and ensure the container is tightly closed when not in use.

The tablet is placed under the tongue and allowed to dissolve completely without chewing or swallowing immediately. Patients should remain upright for at least 30 minutes after the dose and avoid eating or drinking during that time. The first dose is usually taken in a medical setting for observation.

The most serious adverse events are systemic allergic reactions, including anaphylaxis, angioedema, and severe bronchospasm. These reactions can be life‑threatening and require immediate medical attention. Patients should be educated to recognize early signs and have emergency medication, such as epinephrine, readily available if prescribed.

Oralair is contraindicated in individuals with a known hypersensitivity to any component of the tablet or who are experiencing an active systemic allergic reaction. Patients with uncontrolled asthma, severe cardiovascular disease, or those taking medications that increase the risk of angioedema should be evaluated carefully before initiation.